JP2016524602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016524602A5 JP2016524602A5 JP2016512422A JP2016512422A JP2016524602A5 JP 2016524602 A5 JP2016524602 A5 JP 2016524602A5 JP 2016512422 A JP2016512422 A JP 2016512422A JP 2016512422 A JP2016512422 A JP 2016512422A JP 2016524602 A5 JP2016524602 A5 JP 2016524602A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- naltrexone
- subject
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 33
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 230000001404 mediated effect Effects 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 13
- 229960003086 naltrexone Drugs 0.000 claims description 13
- 230000002018 overexpression Effects 0.000 claims description 13
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
- 229960005277 gemcitabine Drugs 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229940044680 immune agonist Drugs 0.000 claims description 4
- 239000012651 immune agonist Substances 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 241000186359 Mycobacterium Species 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 238000009120 supportive therapy Methods 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 2
- 229940002005 zometa Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 239000012646 vaccine adjuvant Substances 0.000 claims 4
- 229940124931 vaccine adjuvant Drugs 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- -1 levramide Chemical compound 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 241000187644 Mycobacterium vaccae Species 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229940084983 cyclophosphamide 50 mg Drugs 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201308440A GB201308440D0 (en) | 2013-05-10 | 2013-05-10 | Therapeutic |
| GB1308440.5 | 2013-05-10 | ||
| PCT/GB2014/051439 WO2014181131A1 (en) | 2013-05-10 | 2014-05-12 | Treatment of cancer with naltrexone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016524602A JP2016524602A (ja) | 2016-08-18 |
| JP2016524602A5 true JP2016524602A5 (OSRAM) | 2017-04-13 |
| JP6346269B2 JP6346269B2 (ja) | 2018-06-20 |
Family
ID=48672126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512422A Active JP6346269B2 (ja) | 2013-05-10 | 2014-05-12 | ナルトレキソンを用いたがんの処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9895438B2 (OSRAM) |
| EP (1) | EP2994137B1 (OSRAM) |
| JP (1) | JP6346269B2 (OSRAM) |
| KR (1) | KR102162038B1 (OSRAM) |
| CN (1) | CN105451740B (OSRAM) |
| AU (1) | AU2014264445B2 (OSRAM) |
| BR (1) | BR112015028269A2 (OSRAM) |
| CA (1) | CA2912203C (OSRAM) |
| GB (1) | GB201308440D0 (OSRAM) |
| IL (1) | IL242533B (OSRAM) |
| MX (1) | MX2015015582A (OSRAM) |
| RU (1) | RU2686325C2 (OSRAM) |
| WO (1) | WO2014181131A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410216D0 (en) | 2014-06-09 | 2014-07-23 | Cancer Vaccine Inst | Therapeutic |
| GB201704911D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
| US20200101066A1 (en) * | 2017-03-28 | 2020-04-02 | LDN Pharma Limited | Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer |
| WO2019055597A1 (en) * | 2017-09-13 | 2019-03-21 | National Tuberous Sclerosis Association, Inc. | Methods and compositions for the treatment of tsc |
| KR20210087454A (ko) * | 2018-11-01 | 2021-07-12 | 파론 파머수티컬스 오와이 | 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제 |
| EP3934648A1 (en) * | 2019-03-06 | 2022-01-12 | LDN Pharma Limited | Method of monitoring treatment |
| GB201903546D0 (en) * | 2019-03-15 | 2019-05-01 | Ldn Pharma Ltd | Cancer treatment |
| CN117545472A (zh) * | 2021-01-25 | 2024-02-09 | Ldn制药有限公司 | 纳曲酮组合物 |
| CN114836529B (zh) * | 2022-03-30 | 2023-05-30 | 唐颢 | Ogfr基因或其编码的蛋白在心肌损伤辅助诊断及治疗中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689332A (en) * | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
| GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| US6136780A (en) * | 1996-03-29 | 2000-10-24 | The Penn State Research Foundation | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor |
| EP0945133A1 (en) * | 1998-03-26 | 1999-09-29 | Lipha | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| US6288074B1 (en) * | 1998-11-17 | 2001-09-11 | Bernard Bihari | Method of treating lymphoproliferative syndrome |
| US6194382B1 (en) * | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
| US6384044B1 (en) * | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
| MXPA04011327A (es) * | 2002-05-17 | 2005-08-15 | Jenken Biosciences Inc | Opioides y compuestos similares a opioides y usos de los mismos. |
| US8017622B2 (en) * | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| GB0509052D0 (en) | 2005-05-04 | 2005-06-08 | Aimsco Ltd | Combination therapy |
| EP2012772A1 (en) * | 2006-04-26 | 2009-01-14 | The Uab Research Foundation | Reducing cancer cell invasion using an inhibitor of toll like receptor signaling |
| US9562014B2 (en) | 2009-07-16 | 2017-02-07 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| NO2453895T3 (OSRAM) * | 2009-07-16 | 2018-10-20 | ||
| GB201410216D0 (en) * | 2014-06-09 | 2014-07-23 | Cancer Vaccine Inst | Therapeutic |
| GB201704911D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
| GB201704909D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
-
2013
- 2013-05-10 GB GB201308440A patent/GB201308440D0/en not_active Ceased
-
2014
- 2014-05-12 CA CA2912203A patent/CA2912203C/en active Active
- 2014-05-12 WO PCT/GB2014/051439 patent/WO2014181131A1/en not_active Ceased
- 2014-05-12 KR KR1020157035176A patent/KR102162038B1/ko active Active
- 2014-05-12 AU AU2014264445A patent/AU2014264445B2/en active Active
- 2014-05-12 MX MX2015015582A patent/MX2015015582A/es unknown
- 2014-05-12 EP EP14725506.1A patent/EP2994137B1/en active Active
- 2014-05-12 JP JP2016512422A patent/JP6346269B2/ja active Active
- 2014-05-12 BR BR112015028269A patent/BR112015028269A2/pt not_active Application Discontinuation
- 2014-05-12 CN CN201480033900.4A patent/CN105451740B/zh active Active
- 2014-05-12 RU RU2015152785A patent/RU2686325C2/ru active
- 2014-05-12 US US14/890,300 patent/US9895438B2/en active Active
-
2015
- 2015-11-10 IL IL242533A patent/IL242533B/en active IP Right Grant
-
2018
- 2018-01-10 US US15/867,177 patent/US20180207263A1/en not_active Abandoned
-
2021
- 2021-10-22 US US17/508,590 patent/US20220040295A1/en not_active Abandoned
-
2023
- 2023-08-16 US US18/234,648 patent/US20230390388A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016524602A5 (OSRAM) | ||
| Sun et al. | Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy | |
| Pietrocola et al. | Caloric restriction mimetics enhance anticancer immunosurveillance | |
| MX2019012462A (es) | Terapia combinada. | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| MA45280B1 (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
| BR112016011078A8 (pt) | derivados de 1-(5-terc-butil-2-arilpirazol-3-il)-3-[2-flúor-4-[(3-oxo-4h-pirido[2,3-b]pirazin-8- il)óxi]fenil]ureia, seus usos, sua composição farmacêutica, método para preparar a mesma e método in vitro para inibir a função raf em uma célula | |
| BR112015026095A2 (pt) | métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral | |
| EP4435112A3 (en) | Compositions and methods for screening solid tumors | |
| JP2007524613A5 (OSRAM) | ||
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| Domingos-Pereira et al. | Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors | |
| MX2019003546A (es) | Virus oncoliticos optimizados y usos de los mismos. | |
| Lei et al. | Jervine inhibits non-small cell lung cancer (NSCLC) progression by suppressing Hedgehog and AKT signaling via triggering autophagy-regulated apoptosis | |
| MX395613B (es) | COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER. | |
| Li et al. | Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? | |
| WO2016191703A3 (en) | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer | |
| Dent | FADD the bad in head and neck cancer | |
| MA49155B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
| WO2017203532A8 (en) | Agents for use in treating drug resistant tumors and triple negative breast cancer | |
| RU2015129366A (ru) | Способы и композиции, относящиеся к лечению злокачественной опухоли | |
| JP2019513826A5 (OSRAM) | ||
| Ghiringhelli et al. | Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study | |
| EA202091579A1 (ru) | Содержащие ганглиозид gm-3 наночастицы в качестве иммуномодуляторов | |
| Ferguson et al. | Vaccination against tumour blood vessels in colorectal cancer |